Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07121413) titled 'A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis' on Aug. 6.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Shanghai Synvida Biotechnology Co.,Ltd.
Condition:
Idiopathic Pulmonary Fibrosis(IPF)
Intervention:
Drug: SV001
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: August 31, 2025
Target Sample Size: 48
Countries of Recruitment:
C...